Diagnosis and management of histoplasmosis

Diagnosis and management of histoplasmosis

Histoplasmosis occurs sporadically or during outbreaks in endemic areas. The risk for severe forms of histoplasmosis is substantially higher among the growing population of immunocompromised patients. Recent research efforts have focused on analyzing epidemics, identifying risk factors for the disea...

Full description

Saved in:
Bibliographic Details
Published in:Current fungal infection reports Vol. 2; no. 2; pp. 94 - 102
Main Authors: McKinsey, David S., McKinsey, Joel P., Brune, Paul R.
Format: Journal Article
Language:English
Published: New York Current Science Inc 01-06-2008
Springer Nature B.V
Subjects:
Animal models
Azoles
Epidemics
Histoplasmosis
HIV
Human immunodeficiency virus
Immunocompromised hosts
Infectious Diseases
Internal Medicine
Medicine
Medicine & Public Health
Occupational Medicine/Industrial Medicine
Patients
Pneumology/Respiratory System
Posaconazole
Risk assessment
Risk factors
Tropical Medicine
Voriconazole
Histoplasmosis
Posaconazole
Solid Organ Transplant Recipient
Voriconazole
Itraconazole
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Histoplasmosis occurs sporadically or during outbreaks in endemic areas. The risk for severe forms of histoplasmosis is substantially higher among the growing population of immunocompromised patients. Recent research efforts have focused on analyzing epidemics, identifying risk factors for the disease, developing improved noninvasive diagnostic assays, and assessing the roles of newer antifungal drugs. Guidelines have been published for the prevention of occupationally acquired histoplasmosis and for reducing the risk of disease in patients with HIV infection. A third-generation Histoplasma antigen assay has been developed, which has superior performance characteristics compared to other noninvasive diagnostic tests. Treatment guidelines for the various clinical forms of histoplasmosis have been formulated and updated. Two newer azoles with activity against Histoplasma capsulatum , voriconazole and posaconazole, have been released; in vitro susceptibility data and animal model results have been reported, and treatment experience with these drugs has accumulated.
ISSN:1936-3761
1936-377X
DOI:10.1007/s12281-008-0015-1